AHA: Renal Denervation Works in Resistant Hypertension
Lowers blood pressure in patients with treatment-resistant hypertension
WEDNESDAY, Nov. 17 (HealthDay News) -- Renal denervation using a catheter-based approach appears to substantially reduce blood pressure, without major adverse events, in patients with treatment-resistant hypertension, according to a study published online Nov. 17 in The Lancet to coincide with presentation at the American Heart Association's Scientific Sessions 2010, held from Nov. 13 to 17 in Chicago.
In the Symplicity HTN-2 Trial, Murray D. Esler, M.D., of the Baker IDI Heart and Diabetes Institute in Melbourne, Australia, and colleagues randomized patients who had a baseline systolic blood pressure of 160 mm Hg or more, despite taking three or more antihypertensive drugs, to either renal denervation with previous treatment or to maintain previous treatment alone.
The investigators found that office-based blood pressure measurements were reduced by 32/12 mm Hg among those who underwent renal denervation, while blood pressure did not differ from baseline among those who maintained previous treatment alone. At six months, 84 percent of patients who underwent renal denervation had a reduction in systolic blood pressure of 10 mm Hg or more, compared with 35 percent of those who maintained previous treatment alone. No differences were found between the groups in terms of serious procedure-related or device-related complications and occurrence of adverse events.
"Catheter-based renal denervation, done in a multicenter, randomized trial in patients with treatment-resistant essential hypertension, resulted in significant reductions in blood pressure," the authors write. "The magnitude of blood-pressure reduction can be predicted to affect the development of hypertension-related diseases and mortality. The technique was applied without major complications."
The study was funded by Ardian; several authors disclosed financial ties to Ardian and other pharmaceutical and medical device companies.